MedWatch

New Pharmatech CEO expects larger external sales – but this won't weaken relationship with Novo Nordisk

Ulla Grove Krogsgaard Thomsen is the new CEO for Novo Nordisk Pharmatech, and according to the CEO, external sales will take up more space in the future. At the same time, she establishes that this will not weaken the firm's relationship with parent company Novo Nordisk.

New CEO for Novo Nordisk Pharmatech Ulla Grove Krogsgaard Thomsen. | Photo: Novo Nordisk Pharmatech / PR

From April 1, Ulla Grove Krogsgaard Thomsen will lead Novo Nordisk Pharmatech, and the future CEO expects sales for the company's external clients will take up an even larger portion during her management in future years, she tells MedWatch.

"Yes, I definitely think that external sales will be taking up even more space. But naturally, we also have our resins foundation, where Novo Nordisk sales take up a large position," Grove Krogsgaard Thomsen says and adds:

Read the whole article

Get 14 days free access.

No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Coloplast upgrades growth expectations following acquisition

Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.

Demant's surgical division loses president of 13 years

Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.

Hearing aid market in US grew by 37 percent in 2021

Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.

Further reading

Related articles

Latest news

See all jobs